Study to Evaluate the Effect on Nitrogen Retention of Two Different Posology Schemes of PKU GOLIKE PLUS 3-16 and Free AAs in Patients With Phenylketonuria
NCT ID: NCT05229549
Last Updated: 2023-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
5 participants
INTERVENTIONAL
2022-05-06
2023-02-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary comparison will be between the test product (PKU GOLIKE PLUS 3-16, a prolonged-release amino-acids (AAs) mixture) and the reference product (an immediate-release free AAs mixture with the same qualitative and quantitative composition of PKU GOLIKE PLUS 3-16). PKU GOLIKE PLUS 3-16 is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
The study will consist of a screening visit (T0), four test days taking place on Sunday (T1-T4), each separated by a washout period (a period of time when a participant is taken off a treatment in order to eliminate its effects) and with the study products being self-administered at home, and a final visit (T5).
Following informed consent and verification of eligibility criteria, 24 patients with PKU will be randomized in a 1:1:1:1 ratio to one of the four randomization sequences ABCD, BDAC, DCBA or CADB.
A, B, C and D will be:
A. One day treatment with 3 self-administrations of GOLIKE PLUS 3-16 (1.2 g/kg total daily dose of AA) B. One day treatment with 2 self-administrations of GOLIKE PLUS 3-16 (1.2 g/kg total daily dose of AA) C. One day treatment with 3 self-administrations of free AAs (1.2 g/kg total daily dose of AA) D. One day treatment with 2 self-administrations of free AAs (1.2 g/kg total daily dose of AA)
GOLIKE PLUS 3-16 and the free AAs mixture will be the only protein substitute allowed on each test day, and no sports activities will be allowed on the test days.
24-hour urines and five blood spots will be collected on each test day. A patient's diary will be used to collect information on patient compliance, 24-hour urines and blood spot collections, diet, daily activities, adverse events and concomitant medications.
Patients completing all four test days will be asked to go to the center for a final visit (T5) taking place within 2 weeks from the last product administration.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A 16 Week Study Evaluating the Introduction of a GMP Based Protein Substitute in Participants With PKU
NCT03771391
PKU EASY Microtabs Plus - Acceptability and Tolerance
NCT06694662
"Gluten Friendly" Treatment in Celiac Disease
NCT03137862
Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal
NCT00669825
Entities and Variables Related to Catch-up Growth
NCT06364735
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary comparison will be between the test product (PKU GOLIKE PLUS 3-16, a prolonged-release amino-acids (AAs) mixture, in this protocol referred to as GOLIKE PLUS 3-16) and the reference product (an immediate-release free AAs mixture with the same qualitative and quantitative composition of PKU GOLIKE PLUS 3-16). PKU GOLIKE PLUS 3-16 is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
The study will consist of a screening visit (T0), four test days taking place on Sunday (T1-T4), each separated by a washout period (a period of time when a participant is taken off a treatment in order to eliminate its effects) and with the study products being self-administered at home, and a final visit (T5). A telephone call will be made to the patients during each washout period. Test days will occur preferably on four consecutive weeks with a 1-week washout period between each test day. Washout can be extended up to 2 weeks in case a dose delay (i.e. delay of the test day) is deemed necessary.
Following informed consent and verification of eligibility criteria, 24 patients with PKU will be randomized in a 1:1:1:1 ratio to one of the following four randomization sequences: ABCD, BDAC, DCBA or CADB.
A, B, C and D will be:
A. One day treatment with 3 self-administrations of GOLIKE PLUS 3-16 (1.2 g/kg total daily dose of AA) B. One day treatment with 2 self-administrations of GOLIKE PLUS 3-16 (1.2 g/kg total daily dose of AA) C. One day treatment with 3 self-administrations of free AAs (1.2 g/kg total daily dose of AA) D. One day treatment with 2 self-administrations of free AAs (1.2 g/kg total daily dose of AA) No change in the randomization sequence will be allowed. Diet will be standardized among different patients in terms of calories and nutrients ranges on each test day, according to the age and body weight of the patients. Moreover, the type of food ingested in 24 hours will be the same on each test day in the same patient.
GOLIKE PLUS 3-16 and the free AAs mixture will be the only protein substitute allowed on each test day, and no sports activities will be allowed on the test days.
24-hour urines and five blood spots will be collected on each test day. Timing of self-administrations, meals and blood spots will be defined for each test day. On the test days, no food will be allowed outside of the defined time windows. The first self-administration of each test day will be performed after overnight fasting (10 -12 h) and before any food intake takes place. Urine should be voided before the first self-administration and not collected. 24-hour urine collection begins thereafter.
The day after each test day a designated courier will collect urine samples and blood spots at the patient's home and will bring them to the center.
A patient's diary will be used to collect information on patient compliance, 24-hour urines and blood spot collections, diet, daily activities, adverse events and concomitant medications.
Adverse events will be continuously monitored during the study, starting from informed consent. Adverse events will be collected by the patients (or by a parent/guardian) in the diary and during the telephone calls made by the Investigator to the patients. Moreover, patients (or parents/guardians) will be instructed to promptly report adverse events occurring during the study to the Investigator.
Patients completing all four test days will be asked to go to the center for a final visit (T5) taking place within 2 weeks from the last product administration. Patients prematurely discontinued from the study will be asked to attend a discontinuation visit possibly taking place within 2 weeks from the last product administration. At the final/discontinuation visit, patients will be asked to return their diaries and the Investigator will verify all information reported in the patient's diary and record it in the electronic Case Report Form (eCRF).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A. One day treatment with 3 self-administrations of GOLIKE PLUS 3-16
GOLIKE PLUS 3-16
PKU GOLIKE PLUS 3-16 is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
B. One day treatment with 2 self-administrations of GOLIKE PLUS 3-16
GOLIKE PLUS 3-16
PKU GOLIKE PLUS 3-16 is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
C. One day treatment with 3 self-administrations of free AAs
Free AAs
It is an immediate-release free AAs mixture with the same qualitative and quantitative composition of PKU GOLIKE PLUS 3-16.
D. One day treatment with 2 self-administrations of free AAs
Free AAs
It is an immediate-release free AAs mixture with the same qualitative and quantitative composition of PKU GOLIKE PLUS 3-16.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GOLIKE PLUS 3-16
PKU GOLIKE PLUS 3-16 is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
Free AAs
It is an immediate-release free AAs mixture with the same qualitative and quantitative composition of PKU GOLIKE PLUS 3-16.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female, aged 3-20 (limits included).
3. Patients with diagnosis of PKU at newborn screening.
4. Patients starting low Phe diet before 1 month of age.
5. Ability and willingness to comply with all study procedures and availability for the duration of the study.
Exclusion Criteria
2. Treatment with therapy for PKU other than amino-acids supplementation.
3. Patients aged \>12 years old with 4 repeated average values of blood Phe \>600 µM in the previous 6 months.
4. Patients aged \<12 years old with 4 repeated average values of blood Phe \>360 µM in the previous 6 months.
5. Any moderate to severe medical condition, which in the opinion of the Investigator would interfere with the study procedures or study outcome (reasoning to be provided), such as history of clinically significant diseases or malfunctions including, but not limited to, gastrointestinal, renal, hepatic, pulmonary, cardiovascular or endocrine disease, hemophilia, hyperlipidemia, impaired glucose tolerance or diabetes (type 1 or 2), or anemia.
6. History of poor co-operation, non-compliance with medical treatments and diet, or poor adherence to investigational procedures.
7. Any current participation in another clinical trial involving investigational or marketed products in the 3 months prior to the inclusion in this study.
8. Pregnancy or lactation.
3 Years
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
APR Applied Pharma Research s.a.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giuseppe Banderali
Role: PRINCIPAL_INVESTIGATOR
ASST Santi Paolo e Carlo, Presidio Ospedale San Paolo, Via Antonio di Rudinì 8 - 20142, Milano (Italy)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Paolo Hospital
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GLK-2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.